11Mar 2025
Finerenone Benefits HFpEF Patients Regardless of Baseline Risk Levels

Finerenone Benefits HFpEF Patients Regardless of Baseline Risk Levels

Finerenone consistently reduces risk in HFpEF patients. The FINEARTS-HF trial (6001 patients, 37 countries) validated PREDICT-HFpEF models, showing accurate risk prediction (C-statistics: 0.68–0.71). Patients in the highest risk quintile had 8–10 times higher event rates. Finerenone’s benefit was consistent across all risk levels, with no significant interaction (P=.24). These findings confirm reliable risk stratification and finerenone's broad therapeutic effect in HFpEF.

  • #cardiology

Like

Save

Share